Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst to Present at Upcoming Investor Conference
04:01pm, Wednesday, 02'nd Apr 2025
RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Hea
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 06'th Mar 2025
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
11:31am, Thursday, 27'th Feb 2025
Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Str
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
11:01am, Wednesday, 26'th Feb 2025
After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisi
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
10:56am, Wednesday, 26'th Feb 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the posit
BioCryst: Orladeyo's Expansion Is Just Getting Started
09:09am, Wednesday, 26'th Feb 2025
BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO, a healthy cash position, and a promising pipeline, making it an attractive investment. Despite a net loss,
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up
07:45am, Wednesday, 26'th Feb 2025
BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies is s
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
06:24pm, Tuesday, 25'th Feb 2025
I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue s
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
06:15pm, Monday, 24'th Feb 2025
Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (BCRX -9.99%) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript
12:17pm, Monday, 24'th Feb 2025
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q4 2024 Earnings Conference Call February 24, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
11:49am, Monday, 24'th Feb 2025
On Monday, BioCryst Pharmaceuticals, Inc. BCRX released results from an interim analysis of the ongoing APeX-P trial.
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
09:10am, Monday, 24'th Feb 2025
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.28 per share a year ago.
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
07:00am, Monday, 24'th Feb 2025
—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)—
– Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function –
BioCryst to Present at Upcoming Investor Conferences
07:00am, Wednesday, 19'th Feb 2025
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
